FDA halts use of Regeneron, Eli Lilly antibody COVID-19 treatments

Jan. 24 (UPI) — The U.S. Meals and Drug Administration on Monday removed monoclonal antibody remedies from the listing of treatments for COVID-19, announcing they are ineffective against the Omicron variant.

the combo of bamlanivimab and estevimab from Eli Lilly and Regeneron’s REGEN-COV might be limited to make use of best while a patient is likely to have been infected with or exposed to “a variant that is liable to these remedies,” the FDA said in an announcement.


Leave a comment

SMM Panel PDF Kitap indir